RNA
NASDAQAtrium Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$11.52+0.01 (+0.09%)
02:15 PM05:30 PM
News · 26 weeks63-100%
2025-12-142026-06-07
Mix1790d
- Insider6(35%)
- Other4(24%)
- SEC Filings3(18%)
- Analyst2(12%)
- Earnings2(12%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Atrium Therapeutics Inc.SCHEDULE 13G - Atrium Therapeutics, Inc. (0002093101) (Subject)
- ANALYSTLeerink Partners initiated coverage on Atrium Therapeutics with a new price targetLeerink Partners initiated coverage of Atrium Therapeutics with a rating of Outperform and set a new price target of $25.00
- SECSEC Form 10-Q filed by Atrium Therapeutics Inc.10-Q - Atrium Therapeutics, Inc. (0002093101) (Filer)
- SECAtrium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)
- PRAtrium Therapeutics Reports First Quarter 2026 Financial ResultsSAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress following its launch as a public company. "Our focused pipeline, strong cash balance and experienced team are driving significant momentum as we build a dedicated precision cardiology company," said Kathleen Gallagher, Pre
- SECSEC Form SCHEDULE 13G filed by Atrium Therapeutics Inc.SCHEDULE 13G - Atrium Therapeutics, Inc. (0002093101) (Subject)
- PRAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationSAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv
- INSIDERSEC Form 4 filed by Kenney Stephanie4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDERSEC Form 4 filed by Hughes Steven George4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDERSEC Form 4 filed by Winslow Brendan R.4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDERSEC Form 4 filed by Gallagher Kathleen P.4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDERSEC Form 4 filed by Hoyos Rocio Martin4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDERSEC Form 4 filed by Younis Husam4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- PRAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of seven non-executive individuals newly hired by the Company. The employees received, in the aggregate, non-qualified stock options to purchase 101,250 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $14.30 per share, the closing price of t
- SECSEC Form S-8 filed by Atrium Therapeutics Inc.S-8 - Atrium Therapeutics, Inc. (0002093101) (Filer)
- SECSEC Form SCHEDULE 13G filed by Atrium Therapeutics Inc.SCHEDULE 13G - Atrium Therapeutics, Inc. (0002093101) (Subject)
- ANALYSTWells Fargo initiated coverage on Atrium Therapeutics with a new price targetWells Fargo initiated coverage of Atrium Therapeutics with a rating of Overweight and set a new price target of $25.00
- PRAtrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic CardiomyopathiesSpinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG. The company is led by Kathl
- SECSEC Form 8-K filed by Avidity Biosciences Inc.8-K - Avidity Biosciences, Inc. (0001599901) (Filer)
- PRAvidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceSAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11, 2026, in Orlando, Florida. 2026 MDA Clinical & Scientific Congress PresentationsOral Presentation: Del-zota Treatment is As
- SECSEC Form DEFA14A filed by Avidity Biosciences Inc.DEFA14A - Avidity Biosciences, Inc. (0001599901) (Filer)
- SECSEC Form 10-K filed by Avidity Biosciences Inc.10-K - Avidity Biosciences, Inc. (0001599901) (Filer)
- SECSEC Form 8-K filed by Avidity Biosciences Inc.8-K - Avidity Biosciences, Inc. (0001599901) (Filer)
- PRAvidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of StockholdersSAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special Meeting") scheduled for February 23, 2026, at 10:00 a.m., Eastern time, and then immediately adjourn proceedings, without conducting any other business. Avidity intends to reconvene the Special Meeting on February 26, 2026, at 10:00 a.m., Eastern time. Stockholders who have already registered for the Special Meeting will not nee
- PRThe New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicingTreatment demonstrated improvements in multiple measures including myotonia, muscle function and strength, mobility and patient-reported outcomesDel-desiran showed acceptable safety and tolerability with most adverse events mild or moderateSAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the final results from the completed Phase 1/2 MARINA® trial of delpacibart eted
RNA FAQ
6 questionsWhat does Atrium Therapeutics Inc. do?
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying...Where does RNA stock trade?
Atrium Therapeutics Inc. (RNA) is listed on NASDAQ.What sector and industry is RNA in?
Atrium Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about RNA?
Atrium Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $2500.00 price target on 2026-05-15. Recent price targets cluster around $2500.00.What companies are similar to RNA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RNA side-by-side with any of them on Quantisnow.How can I track RNA on Quantisnow?
Quantisnow aggregates Atrium Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RNA to receive live email and push alerts on every new disclosure.